Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient preference for subcutaneous versus intravenous rituximab in previously untreated CD20-positive DLBCL or follicular lymphoma
NL-OMON40118Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) (2 arms), sponsored by Roche. Primary endpoint: Overall patient preference for route of rituximab administration. Started Sep 2013; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NL-OMON40118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40118.